The deal adds a high-value late-stage asset with strong Phase II/III data to Eton's rare disease pipeline. Key catalysts to watch: the bioavailability bridging study results and NDA submission in 2H 2027. Leverage of existing HEMANGEOL sales force provides a clear commercial pathway. Patent protection through 2044 offers long-term revenue potential. Monitor for any regulatory or study setbacks that could alter the timeline.
Price Chart
Executive Summary
Eton Pharmaceuticals licensed U.S. rights to late-stage rare disease product candidate ASN-001 (timolol topical gel) from Auson Pharmaceuticals for $3.0M upfront plus up to $33.5M in sales milestones and tiered royalties (10-15%). ASN-001 targets moderate infantile hemangiomas, a large off-label market, and complements Eton's existing HEMANGEOL franchise. Phase II/III data showed 56% elimination/near-elimination at week 24 vs 15% placebo; NDA submission is planned for 2H 2027 with potential launch in 2028.
Key Financial Metrics
Key Facts
- Upfront license fee of $3.0 million paid within 30 days
- Milestone payments totaling up to $33.5 million upon FDA approval and escalating net sales thresholds (from $5M at first commercial sale to $10M at $280M in annual sales)
- Tiered royalties: 10% on cumulative sales ≤$200M, 13% on $200-400M, 15% on >$400M
- Phase II/III trial of 168 patients showed 56% (BID) and 42% (TID) elimination/near-elimination rates at week 24 vs 15% placebo
- NDA submission expected in second half of 2027; potential approval and launch in 2028
- Estimated 20,000 to 30,000 patients annually could be candidates for ASN-001
- Patent protection through 2044 with additional patent application pending
- Leverages existing HEMANGEOL commercial infrastructure and pediatric dermatology relationships
Financial Impact
$3.0M upfront license fee; up to $33.5M in contingent milestone payments; tiered royalties 10-15% on cumulative lifetime sales
Risk Factors
- Regulatory approval risk: ASN-001 requires a bridging study and NDA review by FDA
- Competition from off-label use of ophthalmic timolol products already prescribed by physicians
- Clinical or manufacturing delays in the bridging study or NDA submission timeline
- Milestone and royalty payments are contingent on achieving sales thresholds, which may not materialize
- Potential integration and commercialization execution risk for a new product candidate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-025781 |
| Exhibit: ex_997306.htm | 0001437749-26-025781 |
| Document: 0001437749-26-025781-index-headers.html | 0001437749-26-025781 |
| Document: 0001437749-26-025781-index.html | 0001437749-26-025781 |
| Document: 0001437749-26-025781.txt | 0001437749-26-025781 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $52.88 | awaiting T+60 | — | $51.16 (−3.25%) |
Oct 6, 2026 21d ago | 144 | $54.88 | awaiting T+60 | — | $51.16 (−6.78%) |
Sep 28, 2026 29d ago | 8-K | $59.18 | awaiting T+60 | — | $51.16 (−13.55%) |
Aug 31, 2026 8w ago | Insider Cluster | $60.43 | awaiting T+60 | — | $51.16 (−15.34%) |
Aug 28, 2026 8w ago | Insider Cluster | $60.44 | awaiting T+60 | — | $51.16 (−15.35%) |
Aug 24, 2026 9w ago | Insider Cluster | $63.05 | awaiting T+60 | — | $51.16 (+18.86%) |
Aug 19, 2026 9w ago | 144 | $61.48 | awaiting T+60 | — | $51.16 (+16.79%) |
Aug 5, 2026 11w ago | 8-K | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 5, 2026 11w ago | Press Release | $45.97 | awaiting T+60 | — | $51.16 (+11.29%) |
Aug 4, 2026 12w ago | 8-K | $45.83 | awaiting T+60 | — | $51.16 (+11.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers